No ano passado, Viatris Inc gerou US$ 9.18B em seu segmento de melhor desempenho, Brands. A região United States teve a maior contribuição, com US$ 3.01B no período. No último trimestre, Viatris Inc registrou receita de US$ 2.42B no período encerrado em 2026-06-30, proveniente principalmente do segmento Brands. A região Developed markets teve a maior contribuição, com receita de US$ 2.19B.

Por Empresa

Receita

Proporção

Anual

Anual

Trimestral

Brands

Generics

Complex Gx an dBiosimilars

Central Nervous System and Anesthesia

Respiratory Allergy

Infectious Disease

Gastroenterology

Oncology

Cardiovascular

Diabetes & Metabolism

Other Therapeutic Franchises

Womens Healthcare

Dermatology

Immunology

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Brands

9.18B(64.45%)

9.20B(62.62%)

9.80B(63.69%)

9.89B(60.98%)

10.84B(60.86%)

5.23B(44.29%)

--(--)

Generics

5.07B(35.55%)

5.49B(37.38%)

5.59B(36.31%)

5.02B(30.92%)

5.63B(31.61%)

5.29B(44.75%)

--(--)

Complex Gx an dBiosimilars

--(--)

1.31B(8.10%)

1.34B(7.53%)

1.30B(10.96%)

--(--)

Central Nervous System and Anesthesia

--(--)

1.82B(15.98%)

1.94B(17.19%)

Respiratory Allergy

--(--)

1.80B(15.87%)

1.25B(11.11%)

Infectious Disease

--(--)

1.65B(14.53%)

1.53B(13.57%)

Gastroenterology

--(--)

1.14B(10.02%)

1.12B(9.90%)

Oncology

--(--)

1.05B(9.22%)

758.90M(6.73%)

Cardiovascular

--(--)

887.50M(7.81%)

1.08B(9.59%)

Diabetes & Metabolism

--(--)

831.90M(7.32%)

790.10M(7.01%)

Other Therapeutic Franchises

--(--)

783.20M(6.89%)

1.21B(10.76%)

Womens Healthcare

--(--)

714.70M(6.29%)

708.30M(6.29%)

Dermatology

--(--)

541.00M(4.76%)

778.60M(6.91%)

Immunology

--(--)

150.60M(1.32%)

106.80M(0.95%)

Por Região

Receita

Proporção

Anual

Anual

Trimestral

United States

China (Country)

Developed markets

Emerging Markets

Greater China

JANZ

India

France

Other countries

Northern America

Europe

The Netherlands

Europe - Other

Northern America - Other

Asia

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

3.01B(59.11%)

3.43B(17.14%)

--(--)

3.75B(62.72%)

3.97B(64.13%)

3.87B(63.13%)

4.68B(22.31%)

5.39B(27.20%)

4.85B(51.79%)

4.43B(57.87%)

3.87B(56.40%)

3.89B(57.68%)

3.24B(53.11%)

China (Country)

2.08B(40.89%)

1.91B(9.54%)

--(--)

Developed markets

--(--)

8.93B(44.56%)

9.25B(60.12%)

9.77B(60.23%)

10.43B(58.54%)

--(--)

Emerging Markets

--(--)

2.25B(11.23%)

2.55B(16.58%)

2.62B(16.13%)

3.14B(17.65%)

--(--)

Greater China

--(--)

2.17B(10.81%)

2.16B(14.04%)

2.20B(13.57%)

2.21B(12.42%)

--(--)

JANZ

--(--)

1.35B(6.72%)

1.42B(9.26%)

1.63B(10.07%)

2.03B(11.38%)

--(--)

India

--(--)

1.16B(19.35%)

1.17B(18.94%)

1.16B(19.02%)

1.08B(5.16%)

985.80M(4.98%)

--(--)

France

--(--)

1.07B(17.93%)

1.05B(16.94%)

1.09B(17.85%)

--(--)

Other countries

--(--)

5.88B(27.98%)

4.51B(22.76%)

2.06B(21.97%)

1.62B(21.20%)

--(--)

Northern America

--(--)

5.13B(24.43%)

5.76B(29.10%)

--(--)

Europe

--(--)

4.11B(19.56%)

3.07B(15.52%)

--(--)

1.48B(19.31%)

1.43B(20.85%)

1.30B(19.22%)

1.78B(29.17%)

The Netherlands

--(--)

117.50M(0.56%)

88.30M(0.45%)

66.50M(0.71%)

--(--)

Europe - Other

--(--)

2.14B(22.85%)

--(--)

Northern America - Other

--(--)

251.50M(2.69%)

123.10M(1.61%)

121.50M(1.77%)

167.30M(2.48%)

206.90M(3.39%)

Asia

--(--)

1.44B(20.98%)

1.39B(20.62%)

875.21M(14.33%)